HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on ProQR Therapeutics (NASDAQ:PRQR) and maintained a $5 price target on the stock.
March 14, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProQR Therapeutics maintains a Buy rating and a $5 price target from HC Wainwright & Co., indicating a positive outlook on the stock.
The reaffirmation of a Buy rating and a $5 price target by a reputable analyst like Andrew Fein from HC Wainwright & Co. suggests a strong confidence in ProQR Therapeutics' potential. This endorsement is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100